Related Experiment Videos
Flow cytometric DNA analysis in gynecological oncology
P.A. van Dam1, J.V. Watson, D.G. Lowe
1The joint Gynaecological Oncology Unit, Departments of Gynaecology, Saint Bartholomew's and the Royal Marsden Hospitals, London The Medical Research Council Clinical Oncology Unit, Cambridge The Department of Pathology, Saint Bartholomew's Hospital, London, UK.
Summary
Flow cytometry DNA analysis shows promise for predicting outcomes in ovarian and endometrial cancers. Further research is needed to confirm its role in guiding cancer treatment strategies.
Area of Science:
- Gynecologic Oncology
- Molecular Pathology
- Diagnostic Cytometry
Background:
- Neoplasia in the female genital tract requires accurate prognostic markers.
- Flow cytometric DNA analysis offers a method to assess cellular DNA content and proliferation.
Purpose of the Study:
- To review the utility of flow cytometric DNA analysis in female genital tract neoplasms.
- To evaluate its potential as a prognostic indicator and its limitations.
Main Methods:
- Review of existing literature, primarily retrospective studies.
- Analysis of DNA ploidy and tumor S-phase fraction using flow cytometry.
Main Results:
- DNA ploidy and S-phase fraction show prognostic value in ovarian and endometrial carcinoma.
- Evidence is largely derived from retrospective data.
Conclusions:
- Flow cytometric DNA analysis is a valuable prognostic tool for ovarian and endometrial cancers.
- Prospective studies are essential to validate its role in therapeutic stratification.